BOSP is a successful treatment option for severe periorbital thermal injuries

Article

Using the Boston Ocular Surface Prosthesis (BOSP) on patients with severe periorbtial thermal injuries is a rehabilitating and successful treatment option.

Using the Boston Ocular Surface Prosthesis (BOSP) on patients with severe periorbtial thermal injuries is a rehabilitating and successful treatment option, claims a paper published in Ophthalmology.

Dr Kevin Kalwerisky et al., San Antonio Uniformed Services Health Education Consortium, Texas, USA, conducted a retrospective, interventional case series on 16 eyes of 10 consecutive patients with periorbital thermal injuries. All patients had been treated with the Boston Ocular Surface Prosthesis (BOSP) prior to the investigation. This is an FDA-approved gas-permeable, scleral contact lens.

All patients obtained their injuries through combat mission in Iraq and Afghanistan and were treated for exposure to keratopathy and the BOSP. The main outcome measures included corneal epithelial defect healing, uncorrected visual acuity, best-corrected visual acuity and BOSP wear-time.

After chronic ocular exposure all patients developed vision-threatening ocular surface disease. BOSP enables the rehabilitation of the ocular surface. Of the 16 eyes studied, 10 presented with a corrected visual acuity of 20/70 or better and a best-corrected visual acuity of 20/40 or better was achieved in 5 eyes.

Corneal ulcers were safely and successfully treated in 6 eyes by using the BOSP as a drug delivery vehicle. Only one eye required penetrating keratoplasty, but this was due to direct sequelae of the initial thermal burn.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.